Actively Recruiting

Phase 2
Age: 30Years - 60Years
All Genders
Healthy Volunteers
NCT06745063

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Led by VA Office of Research and Development · Updated on 2025-11-14

50

Participants Needed

1

Research Sites

239 weeks

Total Duration

On this page

Sponsors

V

VA Office of Research and Development

Lead Sponsor

U

University of Missouri-Columbia

Collaborating Sponsor

AI-Summary

What this Trial Is About

The study will assign participants to take either the medication, empagliflozin or a placebo for 12 weeks. The goal of the study is to determine the effects of empagliflozin on arterial health in Veterans with obesity.

CONDITIONS

Official Title

Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity

Who Can Participate

Age: 30Years - 60Years
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Body mass index (BMI) 30-45 kg/m2
  • 30-60 years of age at randomization
  • Evidence of arterial stiffening (defined as Carotid femoral PWV > age-predicted) at screening visit
Not Eligible

You will not qualify if you...

  • Unable to provide consent
  • Diabetes mellitus
  • Uncontrolled hypertension (>180/90mmHg) or systolic <100mmHg at screening visit
  • Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
  • Diagnosis of chronic kidney disease
  • Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
  • Excessive alcohol consumption (>14 drinks/week for men, >7 drinks/week for women)
  • Use of GLP-1 analogs or SGLT2 inhibitors
  • Use of hormone replacement therapy
  • Use of pharmacological therapy for weight loss
  • Body weight changes >10% within the past 6 months
  • History of hypersensitivity to nitrates
  • History of ketoacidosis
  • History of recurrent UTIs or mycotic genital infections
  • Use of anticoagulants
  • Change in anti-hypertensive medication regimen (if in use) during the last 90 days
  • Pregnancy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Harry S. Truman Memorial, Columbia, MO

Columbia, Missouri, United States, 65201-5275

Actively Recruiting

Loading map...

Research Team

J

Jaume Padilla Parellada, PhD

CONTACT

K

Katherine M Burr

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here